Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia

Oncogene

Volumn 34, Issue 27, 2015, Pages 3593-3604

  Schwarzer, A ^a   Holtmann, H ^a   Brugman, M ^a   Meyer, J ^a   Schauerte, C ^a   Zuber, J ^b   Steinemann, D ^a   Schlegelberger, B ^a   Li, Z ^a   Baum, C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLINE; EPHRIN RECEPTOR B3; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; RIBOSOME PROTEIN; SHORT HAIRPIN RNA; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CUX1; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CLONAL EVOLUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; GENOME ANALYSIS; MITOCHONDRION; MOUSE; MURINE MODEL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; RNA TRANSCRIPTION; RNA TRANSLATION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; THYMOCYTE; TRANSLATION REGULATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN SYNTHESIS; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

MURINAE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, T-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84939149349     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.290     Document Type: Article

References (55)

1. Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120: 2032-2041.
2. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 2008; 143: 153-168.
3. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011; 19: 484-497.
4. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
5. Aster JC, Pear WS, Blacklow SC. Notch Signaling in Leukemia. Annu Rev Pathol 2008; 3: 587-613.
6. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298-301.
7. Chiang MY, Xu L, Shestova O, Histen G, L'heureux S, Romany C et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.
8. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007; 110: 278-286.
9. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762-3774.
10. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-1210.
11. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011; 208: 653-661.
12. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW et al. Gene expressionbased chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-342.
13. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013; 24: 766-776.
14. Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 2014; 25: 366-378.
15. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009; 114: 647-650.
16. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengline E et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013; 31: 4333-4342.
17. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med 2011; 208: 1595-1603.
18. Bonnet M, Loosveld M, Montpellier B, Navarro JM, Quilichini B, Picard C et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood 2011; 117: 6650-6659.
19. Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 2012; 21: 459-472.
20. Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY et al. Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov 2013; 3: 908-921.
21. Ren M, Li X, Cowell JK. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood 2009; 114: 1576-1584.
22. Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica 2011; 96: 922-926.
23. Li Z, Beutel G, Rhein M, Meyer J, Koenecke C, Neumann T et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 2009; 113: 2028-2037.
24. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci 2003; 26: 299-330.
25. Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O et al. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci USA 2005; 102: 4016-4021.
26. Pearse RN. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 2005; 105: 4429-4436.
27. Renné C, Minner S, Küppers R, Hansmann M-L, Braüninger A. Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines. Leuk Res 2008; 32: 163-167.
28. Graeber TG, Eisenberg D. Eisenberg-Bioinformatic identification of autocrine loops. Nat Genet 2001; 29: 295-300.
29. Meyer J, Rhein M, Schiedlmeier B, Kustikova O, Rudolph C, Kamino K et al. Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, ?TrkA. Leukemia 2007; 21: 2171-2180.
30. Soulier J. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106: 274-286.
31. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99: 323-334.
32. Ashworth TD, Pear WS, Chiang MY, Blacklow SC, Mastio J, Xu L et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 2010; 116: 5455-5464.
33. Kleppe M, Mentens N, Tousseyn T, Wlodarska I, Cools J. MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context. Haematologica 2011; 96: 779-783.
34. Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB et al. Inactivating CUX1 mutations promote tumorigenesis. Nat Genet 2013; 46: 33-38.
35. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013; 5: 1704-1713.
36. Rhein M, Schwarzer A, Yang M, Kaever V, Brugman M, Meyer J et al. Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models. Ann Hematol 2011; 90: 283-292.
37. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128: 257-267.
38. Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N et al. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget 2012; 3: 869-881.
39. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17: 249-261.
40. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J et al. Targeting capdependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208: 1799-1807.
41. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114: 1618-1627.
42. Lin C-J, Nasr Z, Premsrirut PK, Porco J, John A, Hippo Y, Lowe SW et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep 2012; 1: 325-333.
43. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-3199.
44. Ramsay G, Evan GI, Bishop JM. The protein encoded by the human protooncogene c-myc. Proc Natl Acad Sci USA 1984; 81: 7742-7746.
45. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012; 486: 109-113.
46. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61.
47. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
48. Lee K, Nam KT, Cho SH, Gudapati P, Hwang Y, Park D-S et al. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med 2012; 209: 713-728.
49. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene 2008; 27: 2312-2319.
50. Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J Biol Chem 2008; 283: 23274-23287.
51. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014; 508: 108-112.
52. Dello Sbarba P, Rovida E, Marzi I, Cipolleschi MG. One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a 'hypoxic' environment. Hypoxia 2014; 2: 1-10.
53. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329-341.
54. Lee JY, Nakada D, Yilmaz ÖH, Tothova Z, Joseph NM, Lim MS et al. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 2010; 7: 593-605.
55. Larsson O, Sonenberg N, Nadon R. anota: analysis of differential translation in genome-wide studies. Bioinformatics 2011; 27: 1440-1441.